

NASDAQ: **IDYA**

# IDEAYA Biosciences

Improving Lives  
Through Transformative  
Precision Medicines

## IDEAYA Biosciences Synthetic Lethality Investor Day

April 20, 2021

1:00 pm - 3:00 pm ET

10:00 am - 12:00 pm PT

South San Francisco, California (Virtual)

**Synthetic Lethality Focus**

**IDEAYA and GSK Leaders**

**Key Opinion Leaders**

**– SAVE the DATE –**

Additional Information and Registration

<https://ir.ideayabio.com/events>



# IDEAYA Biosciences – Synthetic Lethality Investor Day

South San Francisco, California (Virtual)

April 20, 2021 1:00 pm - 3:00 pm ET / 10:00 am - 12:00 pm PT

## Agenda Topics

Synthetic Lethality: An Emerging Area within Precision Medicine and GSK-IDEAYA Partnership

IDE397: Targeting MAT2A in MTAP-Deleted Tumors

Werner Helicase: Compelling Synthetic Lethality Target

Pol Theta: Key Target in MMEJ DNA Damage Repair Pathway

PARG: Novel Target in a Clinically Validated Pathway

## Presenters

Yujiro Hata – President, Chief Executive Officer, IDEAYA Biosciences

Michael Dillon, Ph.D. – Senior Vice President, Chief Scientific Officer, IDEAYA Biosciences

Mark Lackner, Ph.D. – Senior Vice President, Head of Biology and Translational Sciences, IDEAYA Biosciences

Matt Maurer, M.D. – Vice President, Head of Clinical Oncology and Medical Affairs, IDEAYA Biosciences

Benjamin Schwartz, Ph.D. – Vice President, Head of Oncology Synthetic Lethality Research Unit, GlaxoSmithKline

William Sellers, M.D. – Core Institute Member and Director of the Cancer Program of the Broad Institute of MIT and Harvard

Alan D'Andrea, M.D. – Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of Harvard Medical School